Inobrodib is a first of its kind treatment for specific cancers.
The current focus is on the treatment of relapsed refractory multiple myeloma, as well as some other specific blood cancers.
CellCentric’s clinical studies have been open in the US and Europe, with current recruitment focused in the UK. Potential suitability for enrolment in an inobrodib clinical trial is made by oncologists at our collaborative, participating hospitals, and not by CellCentric. Any advice on clinical study options should come from your general practitioner and/or oncologist.
Latest press releases